HeartWay Medical-B Reports 2025 Revenue of RMB 408 Million, Achieves Profitability with Strong Growth Across Core Business Segments

Economic Observer NetworkHeartCare-B Announces 2025 Results: Turns Profitable with Revenue Increasing by 46.9% Year-on-Year to RMB 408 Million; Net Profit Attributable to Shareholders at RMB 83.335 Million; Gross Margin Improves to 70.9%; Net Operating Cash Flow Reaches RMB 155 Million.

Operating Performance

In 2025, the company achieved revenue of 408 million yuan (a year-on-year increase of 46.9%), with shareholders' attributable profit reaching 83.335 million yuan, representing a significant turnaround from the net loss of 13.6 million yuan in 2024. Gross margin improved to 70.9%, and net operating cash flow reached 155 million yuan, indicating a marked improvement in profitability quality.。

Business Progress

Hemorrhagic stroke business revenue surged 223.2% year-on-year, ischemic stroke business grew 31.8%, and the star product in the interventional pathway, the vascular closure device, achieved an income of over 100 million yuan. The three major segments synergistically drove a five-year compound annual growth rate of 46%.。

Strategic Advancement

Overseas revenue grew by 101.3% year-on-year in 2025. Core products such as thrombectomy stents have obtained CE/FDA certification, with 56 registration certificates achieved across 13 countries and over 130 additional registrations in progress across 29 countries. The management aims for overseas revenue to contribute over 10% (exceeding 100 million yuan) by 2028.。

Product Development Progress

Company's Invasive Brain-Computer Interface System Completes Animal Experiments, Plans to Conduct First Human Clinical Trial by End of 2026, Technical Pathway Benchmarks International Leading Products. Potential Market Size in This Field Reaches Tens of Billions of Dollars, First-Mover Advantage Draws Market Attention.。

The above content is based on publicly available information and does not constitute investment advice.